HIPRA Biotech Services, HIPRA’s division dedicated to providing development and manufacturing services for biological products to biotechnology and pharmaceutical companies (CDMO), has completed its first year of operations with results exceeding initial expectations and with very positive growth prospects. HIPRA introduced the division in January 2025 and, in just nine months, secured its first agreement, a particularly significant milestone in a sector characterized by long commercial cycles.

Launched with the aim of making HIPRA’s expertise and more than 50 years of experience in biotechnology available to third parties, as well as its scientific, technical, and industrial capabilities, HIPRA Biotech Services offers advanced development and production services for biological products and vaccines. Its offering covers R&D activities, optimization, and industrial scale-up, from early research stages through to large-scale manufacturing.